Navigation Links
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Date:12/5/2008

Presentations Will Highlight Research Conducted in GenVec Malaria Vaccine Program

GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that the company will present on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 57th Annual Meeting, which will take place in New Orleans, LA on December 7-11, 2008. Two presentations, highlighting research conducted in this program, will be given by GenVec scientists. Additional presentations, to be given by GenVec collaborators, will provide updates on malaria vaccine development, ranging from preclinical research through ongoing clinical studies using GenVec's core adenovector technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO)

Joseph L. Bruder, Ph.D., GenVec's Director of Vector and Vaccine Programs, will give two research presentations: "Advanced generation adeno-based vectors for malaria vaccine development" and "Development of a multi-antigen multi-stage adenovector-based malaria vaccine that induces robust T-cell and antibody responses." These presentations will be available on GenVec's website on December 11, 2008. To view these presentations, visit www.genvec.com, click on "Investor Relations" and then "Webcasts and Data."

"Research presented at the ASTMH Annual meeting highlights the potential of GenVec's vaccine programs," stated Dr. Rick King, GenVec's Senior Vice President of Research. "We are excited about the prospective use of our technology in the prevention of malaria."

About GenVec

GenVec, Inc.
'/>"/>

SOURCE GenVec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
8. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. GeneThera Announces it is Set to Begin Commercial Testing for Johnes Disease as Soon as January, 2009.
11. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Akcea ... (NASDAQ: ISIS ), announced today that the ... Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for ... (FCS).  FCS is a rare genetic disease characterized ... pancreatitis. In a Phase 2 study published in ...
(Date:7/5/2015)... , July 6, 2015 Nihon University ... symposium on Medical-Engineering Collaboration "Medicine Definitely Jumps ... 10, 2015 in Tokyo, Japan ... medical applied research will present their achievements and ... a new industry produced with 8K technology. ...
(Date:7/3/2015)... MUMBAI, India , July 4, 2015 /PRNewswire/ ... médicale continue cible les épidémies que sont l,hypertension, ... centrale et du Sud-Est, par l,intermédiaire de plateformes ... ces maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... Prendre en charge le diabète en ligne , ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... Aug. 24 Curemark Founder and CEO Dr. Joan Fallon ... Sequencing 2009 Conference at Harvard Medical School on July 14th. ... this cutting-edge conclave is particularly significant, since epigenetics is the ... a change in the DNA sequence. Presenters at the session ...
... , EMERYVILLE, Calif., Aug. 21 ... NBY ), a clinical stage company developing non-antibiotic anti-infective compounds ... viral, and fungal infections, will deliver two poster presentations at the ... San Francisco, CA. The two poster presentations will describe results ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
(Date:7/4/2015)... ... ... Dating a real millionaire online can be more difficult. Millionairematchapp.com ... to remove the worries from meeting partners. Recently, the site announced they're publishing ... and readers have responded with excitement. , “There's quite a few millionaire dating ...
(Date:7/4/2015)... ... ... When a hacker gains access to someone’s email account, it can lead to all sorts ... the FTC issued a scam alert about a social engineering scam which cons ... reset instigated by the hacker. All they have to do is click for a ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new ... buzz of media attention. In an effort to spread the news, a comprehensive ... "These days many people are feeling overwhelmed by stress and fatigue," reports Hendricks. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top ... mesothelioma with even minimal asbestos exposure. Click here to read the complete story ... of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national chief nursing officer recruitment for ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... method to diagnose lung disease that is based on the ... led a team of researchers in using a sensor employed ... ,The sensor, called a microDMxTM sensor was developed ... detect "unhealthy" molecules emanating from the breath of a patient. ...
... of Quinolone antibiotics for eardrum perforations has been ... disease than the use of systemic antibiotics//. Dr. ... in the Liverpool School of Tropical Medicine, UK ... Cochrane Library that topical quinolone are better than ...
... aspirin to prevent heart problem have increased tremendously//. ... of Public Health (GSPH) and others conducted the study and ... African Americans and diabetics do not opt for aspirin therapy. ... and Europe measured regular use of aspirin among 2,163 African ...
... Griffiths, Ph.D., professor of geriatric medicine, University of Pittsburgh School ... the reduced activity of the orbitofrontal cortex of the brain. ... issue of the Journal of Urology. He studied the brain ... He analyzed the brain activity of 6 normal people and ...
... of breast cancer cases in the UK. As many as ... ductal carcinoma// in situ (DCIS) during 2002. The Cancer Research ... therapy drugs are capable of preventing the recurrence of the ... being studied. The DCIS is considered a pre-cancerous condition, which ...
... fertility kit, which is termed as the Plan Ahead kit comes ... and helps them to decide about their pregnancy//. The kit ... completing all the necessary tests. It gives them a clear view ... and compares it with a standard levels. The results help the ...
Cached Medicine News:Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2Health News:New fertility kit, analyzes the woman's ability to conceive 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: